ReviewOncotarget2015
Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.
Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Article
- Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.Molecular oncology · 2022Article
- Ezh2 harnesses the intranuclear actin cytoskeleton to remodel chromatin in differentiating Th cells.iScience · 2021Article
- Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category.Journal of clinical and experimental hematopathology : JCEH · 2021Review
- Extracellular Vesicles: Schistosomal Long-Range Precise Weapon to Manipulate the Immune Response.Frontiers in cellular and infection microbiology · 2021Review
- Vav1 Down-Modulates Akt2 Expression in Cells from Pancreatic Ductal Adenocarcinoma: Nuclear Vav1 as a Potential Regulator of Akt Related Malignancy in Pancreatic Cancer.Biomedicines · 2020Article
- RAC1 Takes the Lead in Solid Tumors.Cells · 2019Review
- Rac GTPases in Hematological Malignancies.International journal of molecular sciences · 2018Review
- Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes.Oncogenesis · 2018Article
- Article
- The gp130 Cytokine Interleukin-11 Regulates Engraftment of Vav1Stem cells (Dayton, Ohio) · 2018Article
- All-Round Manipulation of the Actin Cytoskeleton by HIV.Viruses · 2018Review
- [Regulatory effect of Vav1 on T cells and its relation to clinical diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2018Review
- CCR7 Is Recruited to the Immunological Synapse, Acts as Co-stimulatory Molecule and Drives LFA-1 Clustering for Efficient T Cell Adhesion Through ZAP70.Frontiers in immunology · 2018Article
- The C1 domain of Vav3, a novel potential therapeutic target.Cellular signalling · 2017Article
- TGFβ promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1.Oncogene · 2017Article
- Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many deregulated signal transducer proteins are involved in various cancers at numerous stages of tumor development. One of these, Vav1, is normally expressed exclusively in the hematopoietic system, where it functions as a specific GDP/GTP nucleotide exchange factor (GEF), strictly regulated by tyrosine phosphorylation. Vav was first identified in an NIH3T3 screen for oncogenes. Although the oncogenic form of Vav1 identified in the screen has not been detected in clinical human tumors, its wild-type form has recently been implicated in mammalian malignancies, including neuroblastoma, melanoma, pancreatic, lung and breast cancers, and B-cell chronic lymphocytic leukemia. In addition, it was recently identified as a mutated gene in human cancers of various origins. However, the activity and contribution to cancer of these Vav1 mutants is still unclear. This review addresses the physiological function of wild-type Vav1 and its activity as an oncogene in human cancer. It also discusses the novel mutations identified in Vav1 in various cancers and their potential contribution to cancer development as oncogenes or tumor suppressor genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.